ALKERMES | ALKS - 债务

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 6.69B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	债务	更改		日
AbbVie	USD 67.5B		67.5B	2025-12
Acadia Pharmaceuticals	USD 52.19M		2.62M	2025-12
ALKERMES	USD 1.58B		1.51B	2026-03
Amgen	USD 54.6B		17M	2025-12
Biogen	USD 6.56B		275.1M	2026-03
BioMarin Pharmaceutical	USD 1.44B		833.74M	2026-03
Bristol-Myers Squibb	USD 47.14B		3.9B	2025-12
Coherus Biosciences	USD 294.92M		1.25M	2025-03
Eli Lilly	USD 42.5B		3.6M	2025-12
Gilead Sciences	USD 24.94B		5M	2025-12
Heron Therapeutics	USD 149.65M		157K	2024-09
Ionis Pharmaceuticals	USD 2.34B		9.5M	2026-03
J&J	USD 47.93B		2.14B	2025-12
Malin Corporation	EUR 100K		0	2023-12
Merck	USD 49.34B		7.97B	2025-12
Minerva Neurosciences	USD 0		0	2024-09
Nektar Therapeutics	USD 0		0	2022-06
Neurocrine Biosciences	USD 406.2M		9.1M	2026-03
Otsuka Holdings	JPY 227.98B		16.47B	2025-12
Ovoca Bio	EUR 0		0	2021-06
Pfizer	USD 63.73B		231M	2026-03
Regeneron Pharmaceuticals	USD 2.71B		300K	2026-03
Vertex Pharmaceuticals	USD 1.99B		44M	2026-03